Pharmacokinetic optimisation of sustained-release bupropion for smoking cessation

Drugs

Volumn 62, Issue , 2002, Pages 11-24

  Johnston, J Andrew ^a   Ascher, John ^a   Leadbetter, Robert ^a   Schmith, Virginia D ^a   Patel, Dipak K ^a   Durcan, Michael ^a   Bentley, Beth ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; AMFEBUTAMONE; AMFEBUTAMONE DERIVATIVE; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CIMETIDINE; CORTICOSTEROID; DESIPRAMINE; HYDROXYBUPROPION; LAMOTRIGINE; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; NICOTINE; PHENELZINE; UNCLASSIFIED DRUG;

ADULT; AGED; ANXIETY; CLINICAL ARTICLE; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CROSS REACTIVITY; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; FEMALE; HUMAN; HYPERTENSION; INCIDENCE; INSOMNIA; MALE; NEUROLOGICAL COMPLICATION; NEUROPATHOLOGY; POPULATION RISK; REVIEW; SMOKING CESSATION; SUSTAINED RELEASE PREPARATION; TOBACCO DEPENDENCE; XEROSTOMIA;

BUPROPION; DELAYED-ACTION PREPARATIONS; DOPAMINE UPTAKE INHIBITORS; FEMALE; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS; SMOKING CESSATION; TOBACCO USE DISORDER; TREATMENT OUTCOME;

NICOTIANA TABACUM;

EID: 0036328290     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262002-00002     Document Type: Review

References (42)

1. Recent trends and sociodemographic distribution of cardiovascular risk factors: Results from two population surveys in the Austrian WHO CINDI demonstration area
2. Nicotine dependence in the United States: Prevalence, trends, and smoking persistence
3. Trends in cigarette smoking in 36 populations from the early 1980s to the mid-1990s: Findings from the WHO MONICA project
4. Cigarette smoking among adults: United States, 1999
5. Towards a tobacco-free world
6. The pharmacology underlying pharmacotherapy for tobacco dependence: A focus on bupropion
7. Bupropion: A review of its mechanism of antidepressant activity
8. The putative role of extra-synaptic mesolimbic dopamine in the neurobiology of nicotine dependence
9. Role of dopamine in the behavioural actions of nicotine related to addiction
10. Noradrenaline in the ventral forebrain is critical for opiate withdrawal-induced aversion
11. A hypothesis for a common neurochemical basis for alcohol and drug disorders
12. Involvement of locus coeruleus projections in opiate withdrawal but not in opiate tolerance in mice
13. Bupropion in depression: I. Biochemical effects and clinical response
14. Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine
15. Bupropion is a nicotinic antagonist
16. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation
17. Bupropion: A review of its use in the management of smoking cessation
18. Smoking cessation in patients with chronic obstructive pulmonary disease: A double-blind, placebo-controlled, randomised trial
19. A comparison of sustained-release bupropion and placebo for smoking cessation
20. The effect of bupropion on nicotine craving and withdrawal
21. Late-term smoking cessation despite initial failure: An evaluation of bupropion sustained release, nicotine patch, combination therapy, and placebo
22. Bupropion for smoking cessation: Predictors of successful outcome
23. Relationship between drug exposure and the efficacy and safety of bupropion sustained-release for smoking cessation
24. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation: A randomized, controlled trial
25. Bupropion to aid smoking cessation
26. Pharmacokinetics of bupropion, a novel antidepressant agent, following oral administration to healthy subjects
27. Cytochrome P450 metabolism of bupropion
28. Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers
29. Single-dose pharmacokinetics of bupropion in adolescents: Effects of smoking status and gender
30. Pharmacokinetics of single- and multiple-dose bupropion in elderly patients with depression
31. Cigarette smoking and clinically significant drug interactions
32. Disposition of bupropion in healthy volunteers and subjects with alcoholic liver disease
33. CYP2B6 mediates the in vitro hydroxylation of bupropion: Potential drug interactions with other antidepressants
34. Carbamazepine but not valproate induces bupropion metabolism
35. Lack of effect of cimetidine on the pharmacokinetics of sustained-release bupropion
36. Effects of steady-state bupropion on the pharmacokinetics of lamotrigine in healthy subjects
37. Alcohol and bupropion pharmacokinetics in healthy male volunteers
38. Bupropion in Parkinson's disease